Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
6.53 USD | +0.31% | -2.97% | -6.71% |
17/05 | HC Wainwright Adjusts Kala Pharmaceuticals Price Target to $18 From $21, Maintains Buy Rating | MT |
02/04 | HC Wainwright Trims KALA BIO's Price Target to $21 From $22, Keeps Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.71% | 18.34M | |
+38.33% | 723B | |
+34.28% | 595B | |
-4.34% | 369B | |
+20.23% | 332B | |
+2.44% | 282B | |
+17.02% | 244B | |
+9.31% | 208B | |
-5.07% | 205B | |
+0.04% | 168B |
- Stock Market
- Equities
- KALA Stock
- News KALA BIO, Inc.
- Kala Pharmaceuticals Receives FDA Nod for Phase 2 Testing of Cornea Treatment, Triggering $25 Million in New Funding